Stock listing

Munich:HDP1 Arrowhead Pharmaceuticals, Inc. Aktie

German listing (Munich) of Arrowhead Pharmaceuticals, Inc. · home listing NASDAQ:ARWR

Follow Arrowhead Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · MUN:HDP1

€52.40 EUR +0.36 (+0.7%)

Close on Oct 27, 2026

Day range
€52.40 – €52.40 EUROct 27, 2026
Market cap
€6.49B EURAt the close on Oct 27, 2026 · price × 123.9M shares outstanding
Arrowhead Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ARWR · Home$59.57 USD-0.33 (-0.6%)1,306,405$60.55$61.17$59.41$59.90Close on Nov 2, 2026
B3:A2RR3439.76 BRL+3.48 (+9.6%)5539.7639.7639.7636.28Close on Oct 27, 2026
LSE:0HI3$59.94 USD+2.018 (+3.5%)270$59.48$60.38$57.67$57.92Close on Oct 27, 2026
Frankfurt:HDP1€52.82 EUR+0.06 (+0.1%)—€53.68€53.68€52.52€52.76Close on Oct 30, 2026
Munich:HDP1€52.40 EUR+0.36 (+0.7%)—€52.40€52.40€52.40€52.04Close on Oct 27, 2026
Ticker
Munich:HDP1
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Munich
Currency
EUR

What changed lately

Calls

Replays

  • Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q3 2026 Earnings Call

    Tue, Aug 04, 2026 · 4:30 PM ET

    Watch Transcript

  • Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q2 2026 Earnings Call

    Thu, May 07, 2026 · 4:30 PM ET

    Watch Transcript

  • Arrowhead Pharmaceuticals (NASDAQ:ARWR) Q1 2026 Earnings Call

    Thu, Feb 05, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

Nov 3, 2026

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

Nov 2, 2026

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

Oct 27, 2026

Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers

Oct 14, 2026

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

Oct 7, 2026

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Sep 29, 2026

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Sep 15, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

Sep 3, 2026

Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia

Aug 30, 2026

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

Aug 24, 2026

All Arrowhead Pharmaceuticals, Inc. news

Decks

Arrowhead Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
54 in the last 12 months · 287 in all · newest Nov 3, 2026 · oldest 2019
Calls
19 calls with a replay · 19 with a transcript · latest Aug 4, 2026
Decks
16 decks · latest Oct 14, 2026

Where Arrowhead Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ARWR · Home listingNASDAQUnited StatesUSD
gettex:HDP1gettexGermanyEUR
B3:A2RR34B3BrazilBRL
LS Exchange:A2AGYBLS ExchangeGermanyEUR
Lang & Schwarz:A2AGYBLang & SchwarzGermanyEUR
BMV:ARWRBMVMexicoMXN
LSE:0HI3LSEUnited KingdomUSD
BOATS:ARWRBOATSUnited StatesUSD
Tradegate:HDP1TradegateGermanyEUR
Frankfurt:HDP1FrankfurtGermanyEUR
Stuttgart:HDP1StuttgartGermanyEUR
BIVA:ARWRBIVAMexicoMXN
BX Swiss:HDP1BX SwissSwitzerlandCHF
Dusseldorf:HDP1DusseldorfGermanyEUR
Hamburg:HDP1HamburgGermanyEUR
Munich:HDP1 · This pageMunichGermanyEUR
Hanover:HDP1HanoverGermanyEUR
Xetra:HDP1XetraGermanyEUR

Log in to ask 6ix AI your own questions about Arrowhead Pharmaceuticals, Inc.